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1. INTRODUCTION 
 
1.1. Bacterial STIs: main pathogens, epidemiological data 
Based on WHO data the most frequent bacterial agents with a proven track record of causing 
venereological diseases (or sexually transmitted infections, STIs), i.e. Chlamydia trachomatis (C. 
trachomatis), Neisseria gonorrhoeae (N. gonorrhoeae) and Treponema pallidum (T. pallidum) are 
responsible globally for about 220 million acute infections per year, such as urogenital 
chlamydiasis, gonorrhoea, syphilis and lymphogranuloma venereum [1]. Based on the records of 
the national epidemiological reporting system (OSZIR: Országos Szociális Információs Rendszer) 
the incidence of these infections in Hungary are in harmony with the global STI-trends; and their 
numbers have reflected an increasing tendency in the last decades. The collated nationwide data 
of 2017 show that altogether 714 acute and past syphilis, 1176 acute gonorrhoeal and 882 acute 
urogenital chlamydial cases were diagnosed last year, which may still underrepresent the current 
epidemiological situation of Hungary [2]. Besides active prevention, one of the most important 
prerequisites of fighting off the spread of STIs is the early diagnosis thereof together with their 
adequate treatment and contact tracing. Albeit there are lots of problems hampering this effort, 
such as the patients’ fear of prejudice and the feeling of being stigmatised, in addition to the 
wanting knowledge regarding relevant sampling, let alone certain pitfalls of laboratory 
diagnostics. The laboratory diagnosis of bacterial STIs should focus on the direct detection of 
pathogens in the case of local infections, while the more invasive and/or systematically 
manifestating venereological diseases can be tested with serological tests. The detection of the 
specific immune response triggered by C. trachomatis L serotypes or T. pallidum serves as a 
reliable diagnostic option [3,4]. In my thesis I have aimed to analyse the current epidemiological 
data focusing on the latter STIs, achieved with modern serological methods in three study groups 
of special relevance: neonates, MSM (men who have sex with men) and pregnant women in 
Hungary. 
 
1.2. C. trachomatis infections  
1.2.1. Urogenitalis infections in adults caused by D-K serotypes 
C. trachomatis infections due to D-K serotypes remain the most frequently reported bacterial 
STIs in the world [1].  The majority of acute chlamydial infections (typically urethritis, cervicitis, 
proctitis) have an asymptomatic course, in as many as 90% of women and almost in 50% of men 
[3].  As a consequence, infected, untreated men may suffer from an epididymitis, while the auto- 
or heteroinoculation of the contaminated genital secretion can cause conjunctivitis in both genders 
as an extragenital manifestation of this STI [3,5]. Heterosexual transmission accounts for a high 
rate, approximately for 90% of the cases [6]. The ascending acute urogenital infection may cause 
a severe, chronic pelvic inflammation (manifestating as endometritis, salpingitis, PID, chronic 
pelvic pain etc.) in 15-40% of untreated women, with a risk of consequent infertility and ectopic 
pregnancy due to tubal damage [7].  
 
1.2.1.1. Relevance and prevention of vertical transmission  
The vertical transmission of C. trachomatis in pregnant women with cervicitis threatens their 
neonates, who may be infected most often via contact route, in the contaminated birth canal. 
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Based on literature data the risk of transmission is between 50 and 70% [8]. The most frequent 
manifestation of neonatal chlamydial infection is a local inflammation of the conjunctivas, called 
ophthalmia neonatorum (ON), which develops in 30-50% of the infected neonates. The onset of 
the invasive infection of the respiratory tract (RTI) occurs at a lower rate, between 10-20% of 
them. Approximately half of the RTI cases are accompanied with the telltale sign of ON 
[9,10,11]. Pertussis, as a clinically similar RTI, may arise as a differential diagnostical problem 
for neonatologists, particularly because chlamydial pneumonia is a so-called „late-type” infection, 
affecting mainly the age group of 4-12 week old neonates, who are partially unvaccinated against 
pertussis [12].  
A generalized screening approach of pregnant women would be a crucial tool of prevention 
completed with the adequate treatment and follow-up aimed to reduce the number of infected 
mothers and thereby the rate of vertical transmission, not to mention the potential maternal 
sequelae of untreated cervicitis. The routine prenatal screening in Hungary currently does not 
include C. trachomatis maternal cervical tests. However, in accordance with the latest 
recommendations of CDC, all pregnant women aged <25 years and those at an increased risk for 
chlamydia should be screened not only at first prenatal visit but should be also rescreened during 
the third trimester [13] 
1.2.1.2. Diagnostic relevance of the systemic immune response in neonates 
Similarly to adults’ uro/-anogenital infections the local inflammation in ON does not induce any 
systemic immune response, which means that serological tests are not useful to diagnose these 
conditions. The more invasive type of C. trachomatis infections, i. e. RTI elicits a specific IgM 
response in neonates, which can be detected for diagnostic purposes. As the maternal IgM does 
not pass across the placenta, the presence of C. trachomatis specific IgM antibody in newborns’ 
blood samples is indicative exclusively of a systemic immune response of the neonates. It is a 
valuable diagnostic tool in supporting the chlamydial etiology [3,14].  
1.2.1.3. Possibilities of laboratory diagnostics in neonatal infections 
The gold standard for the laboratory diagnosis of neonatal C. trachomatis infections regarding 
both ON and RTI is the direct detection of pathogen from relevant clinical samples. Conjunctival 
scrapings or nasopharyngeal aspirates (serving as a reservoir of a more invasive, descending RTI) 
or low respiratory tract specimen are recommended to test for the presence of C. trachomatis [13].  
The increased level of specific IgM concomiting the invasive RTI can be detected using 
serological methods, which may be a useful diagnostic tool even in more chronic, pretreated 
cases, when the sensitivity of PCR has already decreased due to the absence of chlamydial DNA. 
1.2.2. Infections caused by L serotypes: lymphogranuloma venereum (LGV) 
Lymphogranuloma venereum (LGV) is a sexually transmitted disease caused by C. trachomatis 
serotypes L1-3. A primary anogenital ulcer or erosion develops on the initial site of entry of the 
invasive LGV strains causing urethral/rectal discharge and a secondary purulent inguinal 
lymphadenopathy spreading via lymphatics. The classic form of the untreated disease typically 
follows a three-stage course characterised by various, often non-specific symptoms. LGV is 
endemic in tropical, subtropical regions, and only rare, imported cases had been diagnosed in 
Europe before 2003. Recent outbreaks of LGV proctitis among homo-/bisexual men (MSM) in 
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Rotterdam were, however, reported in 2003-2004 and since then the epidemic LGV strains have 
spread all over the European countries threatening mostly the afore mentioned high-risk 
population [15]. Asymptomatic LGV carriers may also serve as an infectious source of the disease 
underlying that the contact-tracing and screening of risk-groups are of great importance [16].  
 
1.2.2.1. Diagnostic relevance of the systemic immune response in LGV 
In contrast to the acute, non-complicated, uro-/anogenital and conjunctival C. trachomatis 
infections caused by D-K serotypes and normally confined to the mucosal epithelium, the invasive 
L serotypes (LGV strains) can cross the epithelium and elicit a strong humoral immune response 
[17].  A strong IgA and IgG seropositivity may provide a presumptive diagnosis completing the 
first-line approaches focusing on the detection of LGV biovar specific DNA. The detection of a 
high level of specific IgA may be an early serological sign of an LGV infection as well as a helpful 
tool to differentiate it from a chlamydial infection due to D-K serotypes [3,18,19].  
1.2.2.2. Possibilities of laboratory diagnostics in LGV 
The definite diagnosis of LGV requires targeted molecular biological assays even for testing 
clinically suspicious cases of high risk sexual behaviour, as the identification of the supposed 
etiological agent at a biovar level is essential for it. Relevant samples as per the actual symptoms 
are needed for confirmation, which most often include ulcer material from primary, anogenital 
lesions or anorectal specimens or inguinal bubo-aspirates. Etiological identification usually 
follows a two-step procedure: after screening the clinical samples for the presence of C. 
trachomatis DNA by a conventional PCR, positive DNA-samples can be further evaluated by an 
LGV-specific real-time PCR, while the actual genotype can be determined by sequencing [16].  
Besides direct detection techniques, serum samples of LGV patients are also suitable for the 
testing of specific IgA and IgG applying various serological assays [19]. The detectable high 
levels of specific antibodies suggest a strong possibility of an LGV infection and suggest a 
repeated sampling and PCR test in case it has failed for any reason. The detection of humoral 
immune response, especially regarding the IgA of predictive value, may contribute to a 
presumptive diagnosis of LGV before the identification of the actual genotype has occurred, in 
accordance with the recommended current LGV guideline of IUSTI [16].  
1.3. T. pallidum subspecies pallidum infection: syphilis 
Syphilis is the third most common bacterial STI in the world exceeded only by C. trachomatis 
infections and gonorrhoea [1]. Trends since 2011 reveal that syphilis rates have been increasing, 
particularly among men, mainly due to an increase among MSM. As the 2015 report of ECDC 
shows, as many as 62% of the cases belonged to the MSM group, while only 9% of the cases 
belonged to females. Infected MSM and heterosexual men represented 8,5 times more cases than 
women alone [20]. Syphilis is a chronic invasive infection caused by T. pallidum subsp. pallidum. 
The untreated disease is characterised by several stages and undulant clinical symptoms, starting 
with a local, painless ulcer on the site of entry, followed by generalised skin eruptions and 
mucosal signs, resulting in late organ damages. Neurological involvement (neurosyphilis) may 
develop at any stage of the infection [21].  
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The efficient recognition of gestational syphilis is affected by several diagnostic pitfalls. 
Spontaneously healing, primary chancres in females are frequently present in hidden anatomical 
sites; while due to the variable, often atypical presentations of secondary syphilitic mucosal or 
skin lesions, a misdiagnosis is a common occurrence [22]. In the latent phases syphilis 
seropositivity may be revealed almost exclusively by screening tests or by contact tracing, which 
makes the routine prenatal screening a very effective means not only of the prevention of 
congenital syphilis but also of the recognition of the maternal infection [23].  A thorough 
venereological examination and exploring the anamnestic data about a risk of a potential exposure 
may call for targeted laboratory tests, which can focus either on the direct pathogen detection or 
serological tests or include both of these depending on the suspected stage of the infection [23]. 
Despite the massive immune response no protective immunity exists in humans against T. 
pallidum [24].  The follow-up of the changes of reagin titres helps to judge the effectivity of the 
treatment or the other way round, even the possibility of another reinfection. Consequently, the 
laboratory diagnostic methods play a crucial role in establishing the actual stage of syphilis in 
patients [4,23].    
1.3.1. Relevance and prevention of vertical transmission of T. pallidum  
Based on estimated WHO data over 900 000 pregnant women were infected globally with 
syphilis in 2012 resulting in serious adverse birth outcomes due to transplacental transmission, 
and threatening the health of the mothers themselves in untreated cases [25].  Women suffering 
from syphilis may infect their fetuses any time during their pregnancy. The possibility of a 
vertical transmission is 70-100% in the primary/secondary stage of gestational syphilis; it 
decreases to 40% in the early latent phase, followed by around 10% in late latent phase, but the 
risk should never be discounted as negligible. The distribution of the potential fetal and neonatal 
consequences depends on the actual level of maternal infectivity [26].  
Congenital syphilis could be theoretically fully prevented with a comprehensive gestational 
screening and by an adequate treatment of seropositive women. Consequently the incidence of 
this condition can be regarded as a negative indicator of any prenatal health care system, while it 
will be always related to the actual prevalence of infectious syphilis among patients of a 
reproductive age [27].  Pregnant women who do not attend routine prenatal care or being infected 
but left undiagnosed after having been screened early in their pregnancy pose the greatest risk to 
their fetuses in terms of congenital syphilis. 
1.3.2. Possibilities of laboratory diagnostics in gestational syphilis 
The current prenatal syphilis screening is regulated by a recommendation in Hungary, and should 
be performed during the first prenatal visit [28]. The laboratory investigation of syphilis combines 
the direct pathogen detection techniques (PCR, dark-field microscopy) suitable for diagnosing the 
infectious phases and the various serological tests aiming the detection of the humoral immune 
response (RPR, VDRL, TPHA, ELISA, immunoblot etc.) The latter assays can be effectively 
performed a few weeks after exposure and they optimally include both aspecific tests (for reagin-
type antibodies) as well as specific tests (for anti-treponemal immunoglobulins). Specific IgG is 
the serological marker of syphilis seroprevalence, i. e. the persistant clue of a past infection, that 
may be detectable even decades long; while the actual phase, i.e. the level of infectivity can be 
concluded from the level of the reagin-type, aspecific antibodies [4,23].  
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Apart from the early, seronegative phase of the infection serological assays make up the „gold 
standard” laboratory diagnostic tool of syphilis, which are appropriate for screening and 
confirming gestational syphilis as well. In the absence of an optimal and reliable method 
representing all the previous advantages of the combined testing in itself, one has several options 
to choose a diagnostical assay, depending on the supposed level of infectivity of the target groups, 
the possibilities of automatisation of the tests and the estimated costs thereof. The aspecific tests 
make up an essential part of syphilis serology, since performed semiquantitatively they usually 
correlate with the disease activity, and their results (titres) can be used to monitor the disease-
activity and the efficacy of treatment, as well as the chance of a potential reinfection [29]. 
Treponemal tests are suitable for the total or separated detection of specific IgG and IgM 
antibodies but they are not helpful in assessing the disease activity and following treatment 
outcome. It should be emphasized that all the laboratory results should be assessed together with 
the anamnestic data and the actual clinical signs and symptoms [22,30].  
2. AIMS  
1. Determination of C. trachomatis seroprevalence among neonates suffering from RTI  
Our aims were the following: 
a)  to determine the C. trachomatis seroprevalence among symptomatic infants suffering 
from RTI in Hungary, compared to data published in the literature; 
b)  to describe the epidemiological features of the seropositive patient group, i.e. the 
distribution of age, gender and the need for hospitalisation compared to patients suffering from 
ophthalmia neonatorum; 
c)  to compare the actual chlamydial serostatus of the study group with their pertussis 
serostatus based on the laboratory database. 
 
2. Detection of C. trachomatis specific immune response among verified LGV patients 
Our aims were the following: 
a)  to test the serum samples of LGV patients in Hungary with ELISA for the presence of 
anti-C. trachomatis IgA and IgG; as well as to evaluate the reactivity pattern of specific IgA and 
IgG by immunoblot technique (unprecedented worldwide, to the best of our knowledge); 
b)  to compare the levels of specific IgA and IgG of LGV patients with the anti-C. 
trachomatis IgA and IgG levels of a non-LGV patient group; as well as to compare the IgG 
immunoblot reactivity pattern of both groups. The non-LGV patients were represented by specific 
IgG seropositive, infertile women of similar age, infected by C. trachomatis D-K serotypes. 
c)  to summarize the practical possibilities of applying the C. trachomatis immunoblot 
technique in the laboratory diagnosis of LGV. 
 
3. Determination of T. pallidum seroprevalence among pregnant women  
Our aims were the following: 
a)  to determine the syphilis seroprevalence in a large prescreened group of pregnant women 
in Hungary during the period 2013-2016, verified for syphilis in our laboratory; as well as to 
compare these results with other seroprevalence data reported from other countries; 
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b)  to determine the semiquantitative RPR titres among seropositive women and to assess the 
actual level of infectivity and the risk of a consequent transmission to their fetuses; 
c)  to analyse the age-distribution among seropositive women and to define the most 
threatened maternal age-group regarding getting infected by syphilis;   
d)  to analyse the given data of gestational age at screening among seropositive pregnant 
women, compared to the actual recommandation for prenatal screening; 
e)  to define the rate of women tested by comprehensive screening versus individual 
venereological investigation due to contact-tracing; and to evaluate the efficacy of prenatal 
screening in revealing gestational syphilis.  
3. MATERIALS AND METHODS  
3.1. Determination of C. trachomatis seroprevalence among neonates suffering from RTI  
3.1.1. Study group, clinical samples 
During the period between January 2008 and December 2016 serum samples were collected from 
262 neonates with clinical symptoms of RTI. The age of the enrolled subjects varied between 1 
and 20 weeks. Forty-one percent of the patients (N=107) were treated in medical institutes in 
Budapest, while 59% of them (N=155) were referred from the countryside. Due to clinically 
similar symptoms the testing of all neonates in the study group was also indicated for pertussis. 
3.1.2. Detection of Chlamydia trachomatis specific IgM 
A micro-immunofluorescence (MIF) test (Focus, Cypress, USA) was chosen used in accordance 
with the manufacturer’s instructions to detect the C. trachomatis-specific IgM in these serum 
samples. The cut-off was defined at a serum dilution rate of 1:32 considered to be diagnostic for 
the infection 17. Based on these results, the patients were divided into 2 main groups. Samples 
of seropositive patients showed an intense, bright-green fluorescence under UV-microscope due 
to the binding of fluoresceine-labeled antihuman-IgM to the chlamydial antigen-human IgM 
complexes. All the other (non-reactive, indeterminate or weak reactive) cases were interpreted 
seronegative.  
3.1.3. Statistical analysis 
A Pearson's chi-squared test (χ2) was used to examine the significance of the relationship between 
the respiratory tract infection by Chlamydia trachomatis and the gender of the neonates. 
3.2. Detection of C. trachomatis specific immune response among verified LGV patients 
3.2.1. Study group, clinical samples 
Our study group consisted of verified LGV patients, whose anogenital samples had been found 
positive for C. trachomaties L1-3 by LGV real-time PCR and by genotyping. We have verified 
altogether 53 LGV cases between September 2012 and December 2017 in Hungary, of whom we 
had received 36 serum samples. The age of the enrolled subjects (N=36) with available serum 
samples varied between 20 and 59 years. The median age in this group was 35.  
3.2.2. Detection of C. trachomatis specific IgA and IgG by ELISA and immunoblot tests  
First, all the serum samples (N=36) of LGV patients were tested for the presence of specific 
antibodies by a commercial C. trachomatis IgA and IgG ELISA (NovaTec, Dietzenbach, 
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Germany), following the manufacturers’ instructions. A further investigation was done with a 
specific IgA and IgG immunoblot assay (GenID Gmbh, Strassberg, Germany). The latter test 
enables the detection of reactivity against the following antigens: some genus-specific antigens, 
such as chlamydial LPS and HSP 60 heat shock-protein (one of the main serological markers of 
tubal infertility); and some species-specific antigens: 40 kDa MOMP1, 29 kDa, 45 kDa and 80 
kDa antigens [31,32].  The reactivity pattern of each immunoblot strip was compared to the 
pattern of the control strips provided with each kit, and was interpreted by a subjective evaluation, 
marked by: (+) when found weak reactivity; + when found equally reactive; ++  or  +++ when 
strong or highly strong reactivity. (The latter designation was used when a confluent dark pattern 
was observed.) The results of the IgA and IgG ELISA, together with those of the IgG immunoblot 
of LGV patients were compared to the results of a group of infertile women (N=36) having been 
previously infected with an ascending type of C. trachomatis D-K, and tested with the same 
serological assays.  
3.2.3. Statistical analysis 
A two-sample Mann-Whitney U-test was used to compare the ELISA IgA and IgG COI (cut-off-
index) values of the serum samples in the LGV group (N=36) versus the infertile women (N=36) 
3.3. Determination of T. pallidum seroprevalence among pregnant women  
3.3.1. Study group, clinical samples 
Large scale serum samples of 49 965 pregnant women were tested by an automated ELISA for 
the presence of specific T. pallidum IgG/IgM antibodies between 2013-2016. All the samples 
showing reactivity (N=527) were submitted for further verification of T. pallidum infection to our 
laboratory. 
3.3.2. Serological methods applied for T. pallidum diagnostics 
Confirmation process included a stepwise performation of combined serological assays of 
different principle. First, the combination of a titrated Rapid Plasma Reagin (RPR) test (Omega 
Diagnostics, Alva, Scotland) and a qualitative Treponema Pallidum Haemagglutination Assay 
(TPHA) (Trinity BioTech, Bray, Ireland) was applied. When both of these tests were found 
negative, the samples were judged seronegative as they had no serological signs of a past or an 
acute syphilis. When any of these tests were found indeterminate or positive, anti-Treponema 
pallidum IgG and IgM ELISA (Euroimmun, Lübeck, Germany) tests were performed.  
All women interpreted as syphilis seropositive had specific anti-Treponemal IgG detected by 
ELISA. The end-titres were also evaluated by a two-fold dilution method of the sera showing 
some RPR activity. A dilution of 1:8 was chosen as the diagnostic cut-off, as RPR>8 titres are 
highly suggestive of an acute/recent infection [13,29,33]. (Based on diluted RPR results 
(negative; 1 8; or >8 ) the seropositive patients were divided into 3 groups. During the 
anonymous analyses of personal data reported by the clinicians only the age and the estimated 
gestational age at sampling were taken into account. Concerning the indication for syphilis testing 
the seropositive patients were revealed either as a result of the recommended prenatal screening 
or due to an individual, random investigation during a targeted contact tracing.  
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4. RESULTS 
4.1. Determination of C. trachomatis seroprevalence among neonates suffering from RTI  
4.1.1. Serological resulst, seroprevalence 
The male to female ratio of symptomatic infants with RTI was 149 male vs 113 female infants 
(ratio 1.3).  Two hundred and thirteen out of 262 affected infants (81.3 %) were hospitalized (126 
male versus 87 female, ratio 1.4). 50 of 262 patients (19.1%) were found unequivocally 
seropositive when tested in the chosen dilution (diagnostic cut-off of 1:32). Altogether 212 infants 
were interpreted as seronegative. According to these results seroprevalence was found 19.1% 
(50/262) in this study group. 
4.1.2. Characterisation of seropositive patients 
The data of specific IgM-positive neonates (N=50) were further analysed according to gender, 
postnatal age as well as the need for hospital care, if any. The age of the seropositive patients 
ranged between 3-20 weeks, the median age being 9 weeks. The gender distribution showed an 
even stronger male dominance of 32 males vs 18 females (ratio 1.8) than the gender distribution 
of the whole study group (ratio 1.3). Eighty percent of seropositive babies needed hospital care 
(40/50), again with a male dominance (25 males vs 15 females, ratio 1.7). Presumably due to the 
low number of patients we could not confirm any significant relation between gender and 
infection (p=0,26). The pertussis serostatus for the study group was also checked in the laboratory 
database but none of the serum samples were reported positive, i.e. Bordetella pertussis as an 
etiological agent could be excluded from a differential diagnostical point of view. 
4.2. Detection of C. trachomatis specific immune response among verified LGV patients 
The age spectrum of the patients involved in the serological investigation (N=36) showed an 
equal distribution throughout the age groups (median age: 35), as 12 cases belonged to 20-30 year 
old group; 13 cases belonged to the 30-40 year old group, while 11 cases to the age group older 
than 40. The distribution of the main clinical manifestations of the LGV infection were as 
follows: proctitis  as a leading sign in 27 patients (75%); inguinal lymphadenopathy in 7 patients 
(19.4%) and urethritis in 2 patients (5.6%).  
4.2.1. ELISA results 
All the tested serum samples (N=36) proved strongly positive for both Chlamydia trachomatis 
IgA and IgG. The ELISA results were calculated in cut-off index (COI) to  facilitate an easier 
comparison. The following formula:𝐶𝑂𝐼 =
𝑂𝐷𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷𝑐𝑢𝑡𝑜𝑓𝑓
  was used to determine the ratio of the optical 
density of the tested serum sample and of the mean optical density value of the cut-off-calibrators 
(given in each kit). The COI values of the IgA ELISA results fell in the range of 1.2 to 11 with a 
median COI of 3.5.  The COI values of the IgG ELISA results fell in the range of 1.4 to 8.5 with a 
similarly high median COI of 3.3.    
4.2.2. Immunoblot results 
As expected, due to the high IgA and IgG ELISA COI values all the tested serum samples (N=36) 
yielded a robust, or even confluent reactivity pattern both on IgA and IgG immunoblot strips. 
Prominent reactive bands were observed to the 40 kDa major outer membrane protein 1 
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(MOMP1), to the 45 kDa protein, to the 80 kDa protein, moreover to the heat shock protein 60 
kDa (hsp60) with a slightly less reactivity in the region of the 29 kDa protein.  
4.2.3. Comparison of serological results  
The non-LGV study group consisted of C. trachomatis seropositive infertile women (median age: 
36). They yielded indeterminate/ positive C. trachomatis IgA results in 66% of samples (median 
COI: 1.25; range: 0.3-2.6). An indeterminate C. trachomatis IgG value was detected in 25% of 
the samples, while 75% of them proved positive for C. trachomatis IgG (median COI: 1.4; range: 
0.9-3.3). The median IgA COI of LGV patients was almost 3 times higher than that of infertile 
patients (3.5/1.25=2.8), while regarding the levels of median IgG COI this ratio was also more 
than twofold that of infertile patients (3.3/1.4=2.35). Due to the two-sample Mann-Whitney U-test 
used to compare the ELISA IgA and IgG COI values, both IgA (U-score=73, p<0,001), and IgG 
levels (U-score=106.5 p<0,001) were found significantly higher among LGV patients versus 
infertile women.  
As all the samples of the infertile women were found positive for C. trachomatis IgG showing 
reactivity by immunoblot they became suitable for comparison with the immunoblot results of the 
LGV patients. Comparing the immunoblot patterns there were no differences on antigen levels 
between the positive IgG results of the LGV and that of the infertile-patients, while the LGV 
patients’ samples showed a much more robust intensity. This was observed especially remarkably 
in the region of the MOMP1 antigen, supported by the detailed marks of our interpretation. 
4.3. Determination of T. pallidum seroprevalence among pregnant women 
Altogether one hundred and forty eight women proved seropositive (specific IgG positive) tested 
by Treponema pallidum ELISA) during this 4 year period (global seroprevalence 2,9‰). 
Seroprevalence was found 2‰ in 2013 (14/6800), 2.7‰ (32/11560) in 2014, 3.4 ‰ (49/14348) in 
2015 and 3‰ (53/17257) in 2016, respectively. The potential infectivity of the seropositive 
samples was assessed by the parallel detected RPR reactivity with a chosen cut-off of higher than 
a 1:8 dilution degree. Based on the observed RPR titres the seropositive pregnant women were 
divided into 3 groups: 
1)  RPR-negative cases indicative of a past infection were found in 53 women (36%);  
2) weakly reactive RPR (titers≤1:8), referring to as either a past or an early acute infection, was 
observed in 55 women (37%).  
3) strong RPR reactivity (titers>8), suggestive of a recent, infectious syphilis, was present in 40 
(27%) of the 148 seropositive women. Half of the latter (20/40) belonged to the age group of 15-
24 years (highlighted in grey in Table 5.), while we found 6 cases of 40 suffering from an active, 
infectious syphilis even in the age group of 35 years or above. The gestational age at sampling 
was reported in 123 of the 148 seropositives cases. Seropositivity was diagnosed in their second 
trimester in 56 of them (45.5%), and in the third trimester in 27 of them (22%). Of these 27 
seropositive women 7 (26%) had serological evidence of a recent, infectious syphilis. Of all the 
seropositive cases, 19 (13%) originated from a random venereological screening, while 129 
(87%) were detected as a result of a routine prenatal screening. Altogether 29 (72.5%) of all 
patients suffering from a presumably acute, infectious syphilis were diagnosed due to prenatal 
screening. 
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5. DISCUSSION 
5.1. Determination of C. trachomatis seroprevalence among neonates suffering from RTI  
As one of the major pathogens causing sexually transmitted infection, C. trachomatis is 
responsible for an estimated 146 million infections per year worldwide, particularly affecting 
young people aged 15-28 years 1,6. The likelihood of women becoming pregnant is increased in 
this age group and those that do may become a maternal source of a potential CT infection in 
newborns. The “classic” type of chlamydial infantile pneumonia is usually a late onset disease, 
typically developing at 4-12 weeks of age, accompanied by a so-called “staccato” cough similar 
to pertussis [12,34]. It can cause a diagnostic challenge, especially in unvaccinated young infants, 
but the real risk of pertussis depends on the actual epidemiological situation, principally when 
similar cases are accumulating and/or no vaccination can be assumed among the contacts. 
The gold standard for the laboratory diagnosis of C. trachomatis RTI is the PCR examination of 
the nasopharyngeal aspirates (or invasively taken respiratory tract samples) for the presence of the 
pathogen 13.  In this study most of the infants had already received some antibiotic treatment, 
rendering the negative results from PCR testing unreliable. In the absence of relevant respiratory 
samples the specific IgM response can be detected with serological assays as a supportive test 
3,14. Male infants appeared to be more vulnerable to RTI than females (ratio 1.3), and also to a 
severe infection requiring hospitalization (ratio 1.4), especially due to a CT-infection (ratio 1.7), 
suggesting that males are more vulnerable to severe CT-RTI. This is very different in infants with 
ON, where the male to female ratio was 0.9 for all ON, 1.0 for CT-ON and 0.6 for severe ON 
requiring hospitalisation. Furthermore, the time of onset of the CT related disease also differed: 
the median age of patients suffering from an early onset-type CT-ON was 2 weeks, while it was 9 
weeks in CT-RTI cases. This is similar to previously reported data 11. Compared to chlamydial 
ON, the rate of hospitalisation from RTI was high: 80 % (vs 6.7% of ON). This is due to the need 
for a more detailed diagnostic procedure, and for a more prolonged therapy and follow-up.  
Based on the positive IgM MIF results (titer ≥32), 50 of 262 infants were diagnosed with C. 
trachomatis infection, which means a 19.1% seroprevalence in this group. These prevalence data 
are far higher than the recently published 7% prevalence based on the direct PCR detection of C. 
trachomatis DNA 35. This discrepancy may be attributed to the different detection methods as 
specific IgM may persist up to 3 months in serum samples, while the chlamydial DNA rapidly 
disappears after an antibiotic treatment 36. The clinical significance of C. trachomatis is 
supported by the observation that it has still been detected as the second most frequent respiratory 
pathogen after RSV of infants less than 6 months old in the Netherlands (35).  
The current prenatal screening system does not include C. trachomatis maternal tests, moreover, 
we have no prevalence data either of pregnant women or of infected neonates. Calculating with 
the range of an estimated 4-8% maternal prevalence and with 90 000-95 000 deliveries per year in 
Hungary, we can safely assume that about 4 000-8 000 pregnant women may be infected by C. 
trachomatis. Being aware of the transmission rate, as many as 2000-5000 newborns can be 
colonised resulting in a symptomatic ON of 700-2800 cases, while RTI of 200-1100 cases. This 
estimated high number of patients indicate focused screening and therapeutic efforts to reduce the 
number of C. trachomatis infected infants, and the routine screening of pregnant women should 
be implemented in order to potentially decrease the rate of vertical transmission. Diagnosed C. 
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trachomatis infections of neonates, however, may not only contribute to better chances of 
recovery of the patient itself but also indicate further STI screenings. It is not uncommon that this 
laboratory diagnosis is the only indirect sign of the latent chlamydial infection of the mother and 
of her sexual partner(s).  
5.2. Detection of C. trachomatis specific immune response among verified LGV patients 
Lymphogranuloma venereum, an STI caused by C. trachomatis L 1-3 serotypes is endemic in 
tropical regions and there had been only imported cases diagnosed in Europe before 2003. During 
2003-2004, however, an LGV outbreak was recognized in Rotterdam and increasing numbers of 
cases have been reported throughout Western-Europe since then [15]. Most LGV-patients belong 
to a high-risk MSM (men who have sex with men) population, who may also be frequently 
infected with other STI agents. Nearly 70% of LGV patients with a known serostatus are HIV 
seropositive [15]. There were almost 1800 LGV cases reported from Europe in 2015, reflecting 
that this condition must be well underreported [37]. LGV only rarely affects heterosexual men or 
women, if so, this is transmitted to them by bisexual men, so called „bridging” persons [38].  
The leading clinical symptom of LGV is proctitis, which gives rise to several differential 
diagnostical problems. The most frequent bacterial STI agents causing infectious proctitis are N. 
gonorrhoeae (30%), C. trachomatis (19%) and T. pallidum (2%) [39]. Co-infections are present 
in about 10% of the patients but in the absence of a targeted venereological examination and 
anamnestic data, the risk factors of exposition are not necessarily revealed during a proctological 
investigation. As the symptoms of proctitis are mainly associated with inflammatory bowel 
diseases (IBD), such as Crohn’s disease or ulcerative colitis, the rectal infections caused by LGV 
or other STI agents are commonly misdiagnosed. There are several case reports of LGV patients 
having been misdiagnosed with IBD, and we have also experienced this false diagnosis in 
minimum 10% of our verified cases in Hungary [40]. Unrecognized, untreated acute LGV is a 
dangerous condition, which may turn into a chronic disease characterised by colorectal fistulas, 
granulomas, ulcerations, the development of fibrotic tissue and a subsequent lymphatic 
obstruction, while the patient itself can infect further persons via unsafe sexual contact [39]. 
Chlamydial seropositivity concomiting this invasive infection is an alarming sign not only for 
acute LGV cases but also for chronic ones representing even more differential-diagnostical 
problems.   
The analysis of the C. trachomatis ELISA tests confirmed that all the samples of the tested LGV 
patients yielded positive IgA and IgG results, while we found a high IgA COI ≥ 2,0 in the 
majority (86%) of the patients. The median values of IgA and IgG ELISA results were several 
folds higher in the group of LGV patients compared to those of infertile patients, which proved to 
be a significant difference. A robust anti-MOMP IgA reactivity, however, can not only be 
associated with a symptomatic LGV, but it is also present in 75% of asymptomatic LGV patients, 
thus providing a valuable diagnostic tool [19]. When compared the results of LGV patients to 
results of those infected by C. trachomatis D-K serotypes we did not find any difference in the 
reactivity pattern, while there was a much more stronger intensity observed in all LGV patients 
due to the extremely high levels of antibodies. Immunoblot assays performed with species-
specific chlamydial antigens are reported highly sensitive and specific, therefore they may serve 
as a reliable serological tool of the presumptive diagnosis of LGV [18,41]. Moreover, they can be 
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applied on a single serum specimen, sent in sporadically to the laboratory, making it a perfect 
choice from practical point of view too [16].  
5.3 Determination of T. pallidum seroprevalence among pregnant women 
The intensified antenatal screening program, launched by the WHO in 2007 resulted in halving 
the seropositive rates among pregnant women between 2008 and 2014 42,43. The varying 
distribution of estimated maternal syphilis across the various geographical regions of the WHO is 
among the lowest in Europe, with an estimated 3.3‰ prevalence in 2008 and 1.5‰  in 2012 44. 
This decreasing trend, which is due to more effective and extended intervention efforts, is also 
reflected by ECDC data, reporting decreased syphilis rates among women from 3.2 to 1.6 per 
100.000 from 2005 to 2013, respectively 6. Although the global syphilis surveillance data 
decreasing between 2008-2012 suggest a substantial progress towards the successful elimination 
of congenital syphilis, there are still many obstacles to overcome 27,44. It should be emphasized 
that the elimination of congenital syphilis will always depend on the actual surveillance strategies 
covering the population of reproductive age. An isolated screening protocol focusing exclusively 
on pregnant women can be regarded as only a suboptimal solution 27.  
The 2.9‰ seroprevalence in Hungarian pregnant women corresponds well to the European data 
published by WHO. Compared to the earlier data of other European countries this value is also 
higher than the reported 1.7‰ in Italy (2006-2007), but lower than the 5.5‰ prevalence in 
Bulgaria (2009-2013) [45,46]. In Ireland a syphilis prevalence ranging annually from 1.4 to 3.3‰ 
was recorded among pregnant women during a 6 year period from 2005 to 2010 [47]. 
Except for the early, seronegative phase of syphilis, serological tests have a crucial role in 
diagnostics. According to international guidelines we chose a combination of RPR and TPHA 
tests as first-step methods for testing the prescreened maternal sera, allowing the parallel 
detection of both aspecific and specific antibodies 4,13. Samples proved to be reactive to RPR 
and/or TPHA tests were further investigated by ELISA. All the patients found IgG positive were 
interpreted as syphilis seropositive, and their infectivity, i.e. the risk of vertical transmission was 
assessed by the level of the titrated RPR.  
Although the dynamic follow-up of reactive RPR of the repeated samples would be optimal, one 
can evaluate the possibility of infectivity even by an RPR titre of a single sample. Based on 
literature data, an RPR titre of 8 was chosen as the diagnostic cut-off, and we decided on a 1:16 or 
higher dilution RPR titre as an indicator of a probable recent, infectious syphilis, with an 
increased risk of a vertical transmission 29,33,48.  The risk of transmission is between 70%-
100% at the stage of symptomatic, primary syphilis, 40% during the early latent phase (<1 year), 
and (still) 10% during late latent syphilis (>1 year) 49. The subgrouping of the seropositives by 
RPR level indicated that at least 27% (40/148) of the confirmed syphilis seropositive pregnant 
women were most likely in the recent, infectious stage of syphilis. Half of the infectious syphilis 
cases were identified among the youngest women aged between 15 and 24 years. Although the 
risk of having a maternal infectious syphilis seems to decrease by age, it is remarkable that we 
have found 6 cases out of the 40 suffering from active, infectious syphilis in the age group of 35 
years or above.  
Despite the general advice to perform screening as early as possible in pregnancy, we confirmed 
almost half of the cases in their 2nd trimester, and one fifth as late as in the 3rd trimester. We do 
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not know the reason for those instances of late testing, but the late presentation for the first 
antenatal care could most likely play a role, especially in multiparous and/or socio-economically 
deprived women, such as drug-users, homeless, etc 33. Treatment for maternal syphilis less than 
1 month before delivery always raises concerns, as it may be too late to prevent neonatal 
complications due to CDC case definition 50. In our series the majority (at least two-third) of 
seropositive women realized they had an infection only during the course of prenatal screening, 
facing the so-called „unexpected seropositivity”. This underlines the crucial role of routine 
syphilis screening not only in order to prevent neonatal cases but also to reveal and to treat their 
own infection. In our series only a minority (13%) of the infected cases were diagnosed by 
venereologists due to contact tracing, while more than half of them (N=11) had RPR levels >8 
suggesting infectious syphilis. Over a period of 4 years, only in the population serviced by our 
laboratory in Hungary, the lack of maternal screening would have missed 29 recent infectious 
cases of syphilis in pregnancy, i.e. at least 7 per year.  
To our best knowledge this was the first study in Hungary aiming to determine the syphilis 
seroprevalence among pregnant women, as well as the demographic and epidemiological features 
of the seropositive mothers. The observed high rate of potentially infectious patients urges for a 
more effective screening strategy, which should include a more concentrated effort in focusing on 
the youngest age-group, as well as involving an increased number of women screened in the first 
trimester. 
6. CONCLUSIONS 
1. Determination of C. trachomatis seroprevalence among neonates suffering from RTI 
a)   a 19.1% C. trachomatis seroprevalence was found among symptomatic neonates suffering 
from RTI tested with a specific IgM MIF assay. The seroprevalence found corresponds to some 
earlier published data and may well reflect the actual risk of infection in the absence of prenatal 
screening. According to some reports, C. trachomatis may be the second most common RTI-
pathogen in this age group second only to RSV-infections [35]. Summarizing our findings, a 
parallel RSV-testing of this patient group would be much more reasonable than the current 
clinical approach focusing on pertussis. 
b)  this condition is described as a so called „late-onset” RTI affecting most often neonates 
aged 2 months. It was supported also by our serological analysis in this patient group with a 
median age of 9 weeks (versus ON patients with a median age of 2 weeks). Due to the severity of 
RTI 80% of them required hospital care (vs 6.7% of ON patients). In spite of only a low number 
of seropositives, our results support the observation regarding the increased vulnerability of male 
infants towards RTIs, especially towards the more serious infections requiring hospitalization 
[51]. Male gender dominance was not present among ON patients. 
c)  as this age-group is partially unvaccinated against pertussis, we would like to emphasise 
that all neonates suffering from pertussis-like symptoms should be tested for C. trachomatis too. 
Based on our results there is a very low risk of being infected by B. pertussis compared to C. 
trachomatis, as we could not confirm any pertussis cases among the tested population during this 
long study period.  
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2. Detection of C. trachomatis specific immune response among LGV patients 
a)   the  ELISA and immunoblot results of the verified LGV cases in Hungary corresponds to 
the literature data reporting elevated specific IgA and IgG production due to this invasive type of 
infection. Especially the detection of a high IgA level can be an adequate predictor of an actual 
LGV. The ELISA test based intense anti-MOMP IgA reactivity published earlier was also 
observed on the immunoblot strips, first described by ourselves as having applied this method. 
b)  we have compared the C. trachomatis ELISA IgA and IgG results, as well as the IgG 
immunoblot reactivity of the LGV study-group to those of a non-LGV patient group of infertile 
women suffering form an ascending type of Chlamydia trachomatis D-K infection. We have 
found that the samples of the LGV patients yielded significantly higher levels of IgA and of IgG 
than those of the infertile patients, characterised by a strong positive IgA response among LGV 
patients. The median ELISA COI values of both tested antibodies proved at least twice higher 
among LGV patients than in infertile patiens.  
c)  irrespectively from the chosen serological method, the strong positive IgA and IgG results 
may have a diagnostic impact as well, indicating further testing for a suggestive LGV. In case of 
large numbers of specimens we suggest that a C. trachomatis ELISA test be used.  Having a low 
number of sporadic LGV cases, the use of immunoblot is more informative and cost-effective, 
even when testing a single sample for presumptive diagnostic purposes. As a valuable diagnostic 
tool it can raise awareness to the necessity of a targeted investigation of the relevant anogenital 
samples in asymptomatic or misdiagnosed LGV patients, especially as an ideal screening 
technique for IBD patients. Due to difficulties of contact tracing among MSM popultions and to 
frequent co-infections, serological testing may serve not only as a diagnostic tool but it is also 
suitable for complex STI screening purposes. 
 
3. Determination of T. pallidum seroprevalence among pregnant women 
a)   The 2.9‰ syphilis seroprevalence found in the pregnant population tested between 2013–
2016 counts as an average value compared to the earlier published European seroprevalence data, 
but exceeds the 1.5‰ value of 2012 as estimated by the WHO.  
b)  at least 27% of the seropositive group (N=148) has a probable active, infectious syphilis, 
characterised by the highest risk (70-100%) of a vertical transmission. As one can count with the 
possibility of being tested in an early phase of infectious syphilis in patients having RPR titres≤8, 
its risk could not be excluded among them either. 
c)  we found that high-risk, infectious syphilis occurred in every age-group, even among 
those older than 35 years, nevertheless, the youngest mothers of 15-24 years yielded the half of all 
cases with probable acute syphilis.  
d) instead of the recommended visit during the first trimester of the pregnancy, almost half 
of the 123 seropositive patients were diagnosed in the second, a fifth of them as late as in the third 
trimester. The latter rate is highly alarming as any therapy given within one month of delivery is 
regarded inadequate, increasing the risk of a connatal syphilis. 
e)  the efficacy of a routine prenatal screening versus random venereological testing was 
supported by the fact that almost three quarter of the high risk pregnant women were diagnosed 
through the former. Consequently, the routine prenatal screening still has a very important role in 
revealing gestational syphils and preventing congenital syphilis. 
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